Agendia’s MammaPrint® and BluePrint® Breast Cancer Tests Selected by Unicancer for French Patients

Product News   May 15, 2018

 
Agendia’s MammaPrint® and BluePrint® Breast Cancer Tests Selected by Unicancer for French Patients

Credit: Agendia

 
 
FURTHER INFORMATION
 
 
 

Related Product News

sphingotec is Adding an Advanced POC Testing Platform to Portfolio

Product News

POC testing of penKid® and bio-ADM® is set to add significant clinical benefit to emergency departments and intensive care units allowing on-site diagnosis, monitoring, and guidance in therapies of sepsis, decongestion in heart failure and acute kidney injury, thereby improving outcomes in acute heart failure, sepsis and other acute settings.

READ MORE

QIAGEN welcomes WHO’s Essential Diagnostics List which includes QuantiFERON-TB Gold

Product News

The World Health Organization recommends IGRA tests in the First Edition of Essential In Vitro Diagnostics.

READ MORE

Ram Group Next Generation Sensor Platform Will Bring Point-of-Care Diagnostics and Wearables to Emerging Markets to Address Global Health Issues

Product News

Ram Group aims to introduce revolutionary low-cost point-of-care diagnostics and healthcare monitoring devices to low-income communities.

READ MORE

Like what you just read? You can find similar content on the communities below.

Cancer Research Diagnostics Proteomics & Metabolomics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE